These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 22833052)
1. Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia. Ong HX; Traini D; Cipolla D; Gonda I; Bebawy M; Agus H; Young PM Pharm Res; 2012 Dec; 29(12):3335-46. PubMed ID: 22833052 [TBL] [Abstract][Full Text] [Related]
2. Epithelial profiling of antibiotic controlled release respiratory formulations. Ong HX; Traini D; Bebawy M; Young PM Pharm Res; 2011 Sep; 28(9):2327-38. PubMed ID: 21614637 [TBL] [Abstract][Full Text] [Related]
3. In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation. Ong HX; Benaouda F; Traini D; Cipolla D; Gonda I; Bebawy M; Forbes B; Young PM Eur J Pharm Biopharm; 2014 Jan; 86(1):83-9. PubMed ID: 23851077 [TBL] [Abstract][Full Text] [Related]
4. Optimization of inhalable liposomal powder formulations and evaluation of their in vitro drug delivery behavior in Calu-3 human lung epithelial cells. Yu S; Yuan H; Chai G; Peng K; Zou P; Li X; Li J; Zhou F; Chan HK; Zhou QT Int J Pharm; 2020 Aug; 586():119570. PubMed ID: 32593649 [TBL] [Abstract][Full Text] [Related]
5. Inhalable liposomal powder formulations for co-delivery of synergistic ciprofloxacin and colistin against multi-drug resistant gram-negative lung infections. Yu S; Wang S; Zou P; Chai G; Lin YW; Velkov T; Li J; Pan W; Zhou QT Int J Pharm; 2020 Feb; 575():118915. PubMed ID: 31816354 [TBL] [Abstract][Full Text] [Related]
6. Model Calculations of Regional Deposition and Disposition for Single Doses of Inhaled Liposomal and Dry Powder Ciprofloxacin. Martin AR; Finlay WH J Aerosol Med Pulm Drug Deliv; 2018 Feb; 31(1):49-60. PubMed ID: 28708440 [TBL] [Abstract][Full Text] [Related]
7. Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection. VanDevanter DR; Gonda I; Dahms J; Cipolla D; Davis AM; Chalmers JD; Froehlich J Clin Microbiol Infect; 2019 Dec; 25(12):1532-1538. PubMed ID: 31035017 [TBL] [Abstract][Full Text] [Related]
8. Anti-microbial Effect and in Vivo Ocular Delivery of Ciprofloxacin-loaded Liposome through Rabbit's Eye. Feghhi M; Sharif Makhmalzadeh B; Farrahi F; Akmali M; Hasanvand N Curr Eye Res; 2020 Oct; 45(10):1245-1251. PubMed ID: 32045531 [No Abstract] [Full Text] [Related]
10. Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections. Lin Y; Chang RYK; Britton WJ; Morales S; Kutter E; Li J; Chan HK Eur J Pharm Biopharm; 2019 Sep; 142():543-552. PubMed ID: 31398437 [TBL] [Abstract][Full Text] [Related]
11. Sweetening Inhaled Antibiotic Treatment for Eradication of Chronic Respiratory Biofilm Infection. Loo CY; Lee WH; Lauretani G; Scalia S; Cipolla D; Traini D; Young P; Ong HX Pharm Res; 2018 Feb; 35(3):50. PubMed ID: 29417313 [TBL] [Abstract][Full Text] [Related]
12. In vitro evaluation of nebulization properties, antimicrobial activity, and regional airway surface liquid concentration of liposomal polymyxin B sulfate. Desai TR; Tyrrell GJ; Ng T; Finlay WH Pharm Res; 2003 Mar; 20(3):442-7. PubMed ID: 12669966 [TBL] [Abstract][Full Text] [Related]
13. Tailored Nanocarriers for the Pulmonary Delivery of Levofloxacin against Pseudomonas aeruginosa: A Comparative Study. Derbali RM; Aoun V; Moussa G; Frei G; Tehrani SF; Del'Orto JC; Hildgen P; Roullin VG; Chain JL Mol Pharm; 2019 May; 16(5):1906-1916. PubMed ID: 30900903 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of neutral and negatively charged liposome-loaded gentamicin on planktonic bacteria and biofilm communities. Alhariri M; Majrashi MA; Bahkali AH; Almajed FS; Azghani AO; Khiyami MA; Alyamani EJ; Aljohani SM; Halwani MA Int J Nanomedicine; 2017; 12():6949-6961. PubMed ID: 29075113 [TBL] [Abstract][Full Text] [Related]
15. Microfluidics assembly of inhalable liposomal ciprofloxacin characterised by an innovative in vitro pulmonary model. Zhang Y; Wong CYJ; Gholizadeh H; Aluigi A; Tiboni M; Casettari L; Young P; Traini D; Li M; Cheng S; Ong HX Int J Pharm; 2023 Mar; 635():122667. PubMed ID: 36738806 [TBL] [Abstract][Full Text] [Related]
16. Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: a time-kill study. Rukholm G; Mugabe C; Azghani AO; Omri A Int J Antimicrob Agents; 2006 Mar; 27(3):247-52. PubMed ID: 16472992 [TBL] [Abstract][Full Text] [Related]
17. Co-Delivery of Ciprofloxacin and Colistin in Liposomal Formulations with Enhanced In Vitro Antimicrobial Activities against Multidrug Resistant Pseudomonas aeruginosa. Wang S; Yu S; Lin Y; Zou P; Chai G; Yu HH; Wickremasinghe H; Shetty N; Ling J; Li J; Zhou QT Pharm Res; 2018 Aug; 35(10):187. PubMed ID: 30094660 [TBL] [Abstract][Full Text] [Related]
18. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study. Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830 [TBL] [Abstract][Full Text] [Related]
19. Mucoadhesive liposomes as ocular delivery system: physical, microbiological, and in vivo assessment. Mehanna MM; Elmaradny HA; Samaha MW Drug Dev Ind Pharm; 2010 Jan; 36(1):108-18. PubMed ID: 19656004 [TBL] [Abstract][Full Text] [Related]
20. Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa. Antonela Antoniu S Expert Rev Anti Infect Ther; 2012 Dec; 10(12):1439-46. PubMed ID: 23253321 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]